No Data
JMP Securities Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $6
Optimistic Buy Rating for Vor Biopharma Amid Promising Clinical Developments and Stable Financial Position
Wedbush Maintains Vor Biopharma(VOR.US) With Buy Rating, Cuts Target Price to $7
Express News | Oppenheimer Reiterates Outperform on Vor Biopharma, Maintains $8 Price Target
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Skye Bioscience (SKYE) and Bristol-Myers Squibb (BMY)
Stifel Maintains Buy on Vor Biopharma, Lowers Price Target to $5
